Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Perrigo Licenses Prescription Brands to Medimetriks Pharmaceuticals

By Pharmaceutical Processing | October 28, 2008

Medimetriks Pharmaceuticals has announced that the company has entered into a licensing agreement with Perrigo Company for the U.S. marketing rights to Centany(R) Ointment and two prescription keratolytic brands. Patented through 2018, Centany(R) represents an important step in Medimetriks’ plan to commercialize patent-protected therapies for the Dermatology and Podiatry markets that offer important patient benefits. Medimetriks plans to launch Centany(R) in early 2009, with the two additional products following shortly thereafter. Previously marketed by Johnson & Johnson’s OrthoNeutrogena professional division, Centany(R) is indicated for the topical treatment of impetigo due to Straphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. Centany(R) received a New Drug Approval in December of 2002 based in part on the unique properties of its vehicle, which offers important benefits over its competitors. The two prescription keratolytic brands are urea-based therapies indicated for the treatment of severe dry skin. They are offered in delivery systems that are gaining wide acceptance in the Dermatology and Podiatry markets and are both patent pending. These new brands will compete in a skin softening market that approaches one million prescriptions annually. “We are happy to have a partner that brings such a record of success in the branded pharmaceutical business,” stated Sharon Kochan, Executive Vice President of Perrigo. “We believe the licensed products are in good hands given Medimetriks management’s proven abilities in building a successful business in the Dermatology and Podiatry markets.” Medimetriks President and CEO, Bradley Glassman, commented, “We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core Dermatology and Podiatry audiences and their patients.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE